Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations

Table 2 Prognostic evaluation of the clinical-genomic and clinical signatures among the ADC and SCC patients in the corresponding training and validation sets

Datasets	Subtype	Type of signature	HR (95 % CI)	p-value^*	p-value^**
Training sets	ADC	Clinical-genomic	2.63 (1.95–3.53)	8.377e–11	4.76e–7
	ADC	Clinical	2.72 (1.62–4.55)	7.064e–5	0.0015
	SCC	Clinical-genomic	4.06 (2.20–7.46)	3.176e–6	1.87e–5
	SCC	Clinical	2.72 (1.36–5.45)	0.002	0.029
Validation sets	ADC	Clinical-genomic	2.1 (1.12–3.93)	0.01	0.008
	ADC	Clinical	2.09 (0.86–5.06)	0.05	0.06
	SCC	Clinical-genomic	1.56 (1.10–2.24)	0.007	0.019
	SCC	Clinical	1.42 (0.89–2.25)	0.07	0.121

ISSN: 1471-2164